Study of SYH2039 in Participants With Advanced Solid Tumors

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD and preliminary anti-tumor activity of SYH2039 in adult patients with selected advanced or metastatic advanced solid tumors who are unresponsive to standard of care therapy. SYH2039 is a small molecule inhibitor of methionine adenosyltransferase 2 alpha (MAT2A).
Epistemonikos ID: 1b3396ee4f9235ec772a223e7521d87e6904434d
First added on: Sep 01, 2024